ATE313326T1 - VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß - Google Patents

VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß

Info

Publication number
ATE313326T1
ATE313326T1 AT99914882T AT99914882T ATE313326T1 AT E313326 T1 ATE313326 T1 AT E313326T1 AT 99914882 T AT99914882 T AT 99914882T AT 99914882 T AT99914882 T AT 99914882T AT E313326 T1 ATE313326 T1 AT E313326T1
Authority
AT
Austria
Prior art keywords
cabergoline
ßrestless
treat
legs syndrome
syndrome
Prior art date
Application number
AT99914882T
Other languages
English (en)
Inventor
Peter Schueler
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE313326T1 publication Critical patent/ATE313326T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99914882T 1998-03-27 1999-03-24 VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß ATE313326T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27
PCT/US1999/004269 WO1999048484A2 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Publications (1)

Publication Number Publication Date
ATE313326T1 true ATE313326T1 (de) 2006-01-15

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914882T ATE313326T1 (de) 1998-03-27 1999-03-24 VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß

Country Status (23)

Country Link
US (1) US6114326A (de)
EP (1) EP1066038B1 (de)
JP (1) JP2002507562A (de)
KR (1) KR100597517B1 (de)
CN (1) CN1303286A (de)
AT (1) ATE313326T1 (de)
AU (1) AU747751B2 (de)
BR (1) BR9908953A (de)
CA (1) CA2320204A1 (de)
CZ (1) CZ297284B6 (de)
DE (1) DE69929041T2 (de)
DK (1) DK1066038T3 (de)
EA (1) EA002554B1 (de)
ES (1) ES2255255T3 (de)
HU (1) HUP0101954A3 (de)
IL (1) IL138522A0 (de)
NO (1) NO20004799L (de)
NZ (1) NZ507176A (de)
PL (1) PL343593A1 (de)
SK (1) SK13312000A3 (de)
TR (1) TR200002759T2 (de)
WO (1) WO1999048484A2 (de)
ZA (1) ZA200004452B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
WO2002078744A1 (fr) * 2001-03-30 2002-10-10 Toray Industries, Inc. Remedes contre la psychonevrose
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
KR100784341B1 (ko) 2002-04-05 2007-12-13 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
EP1534289B2 (de) 2002-08-30 2012-02-22 Kyowa Hakko Kogyo Co., Ltd. Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP2386547B1 (de) * 2005-12-29 2018-06-20 Lexicon Pharmaceuticals, Inc. Multizyklische Aminosäurederivate und Verwendungsverfahren dafür
EP2007369A4 (de) * 2006-04-03 2009-07-01 Teva Pharma Verwendung von rasagilin zur behandlung des syndroms der ruhelosen beine
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (de) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medikament zur Behandlung von Endometriose
EP1987815A1 (de) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2067780A1 (de) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergolin-Derivate als selektive Radikalfänger für Neuronen
AU2010223323B2 (en) 2009-03-10 2013-07-04 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2021067751A1 (en) 2019-10-03 2021-04-08 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
CN117100245A (zh) 2017-01-05 2023-11-24 诺克特丽克丝健康公司 不宁腿综合征或过度活跃神经治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
KR20010052222A (ko) 2001-06-25
PL343593A1 (en) 2001-08-27
AU3353199A (en) 1999-10-18
EA200000994A1 (ru) 2001-02-26
EP1066038A2 (de) 2001-01-10
KR100597517B1 (ko) 2006-07-10
ES2255255T3 (es) 2006-06-16
DK1066038T3 (da) 2006-04-24
TR200002759T2 (tr) 2001-02-21
NO20004799L (no) 2000-10-11
WO1999048484A2 (en) 1999-09-30
CA2320204A1 (en) 1999-09-30
AU747751B2 (en) 2002-05-23
CZ20003419A3 (cs) 2002-01-16
BR9908953A (pt) 2000-12-05
CN1303286A (zh) 2001-07-11
CZ297284B6 (cs) 2006-10-11
JP2002507562A (ja) 2002-03-12
DE69929041D1 (de) 2006-01-26
IL138522A0 (en) 2001-10-31
HUP0101954A3 (en) 2002-09-30
NZ507176A (en) 2003-09-26
NO20004799D0 (no) 2000-09-26
WO1999048484A3 (en) 1999-11-25
SK13312000A3 (sk) 2001-05-10
HUP0101954A2 (hu) 2001-12-28
EP1066038B1 (de) 2005-12-21
US6114326A (en) 2000-09-05
ZA200004452B (en) 2002-02-27
EA002554B1 (ru) 2002-06-27
DE69929041T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69831406D1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE69802828T2 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
DE60213230D1 (de) Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066038

Country of ref document: EP

REN Ceased due to non-payment of the annual fee